Last reviewed · How we verify
B12019 and Neulasta
B12019 and Neulasta is a Biologic drug developed by Cinfa Biotech. It is currently in Phase 1 development.
At a glance
| Generic name | B12019 and Neulasta |
|---|---|
| Sponsor | Cinfa Biotech |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B12019 and Neulasta CI brief — competitive landscape report
- B12019 and Neulasta updates RSS · CI watch RSS
- Cinfa Biotech portfolio CI
Frequently asked questions about B12019 and Neulasta
What is B12019 and Neulasta?
B12019 and Neulasta is a Biologic drug developed by Cinfa Biotech.
Who makes B12019 and Neulasta?
B12019 and Neulasta is developed by Cinfa Biotech (see full Cinfa Biotech pipeline at /company/cinfa-biotech).
What development phase is B12019 and Neulasta in?
B12019 and Neulasta is in Phase 1.
Related
- Manufacturer: Cinfa Biotech — full pipeline
- Compare: B12019 and Neulasta vs similar drugs
- Pricing: B12019 and Neulasta cost, discount & access